C5 and paroxysmal nocturnal hemoglobinuria: This report provides the first clinical and pharmacokinetic evidence suggesting that third‐trimester use of pegcetacoplan may be a viable treatment option in select pregnant patients with PNH with suboptimal response to C5 inhibitors.